My view on current and future use of JAK inhibitors for ET, PV, and MF

My view on current and future use of JAK inhibitors for ET, PV, and MF

User Photo
HMP CME

2 years
23,399 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view on the current and future use of JAK inhibitors for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology

© 2017 Imedex, LLC.
Up Next Autoplay